Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum
– Prescription Drug User Fee Act goal date extended by three months to September 23, 2021 – WEST CHESTER, Pa., May 28, 2021 -- Verrica Pharmaceuticals Inc. , a dermatology... | May 28, 2021